Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allegra Dry Syrup in Pediatric Perennial Allergic Rhinitis
NCT01244217Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of fexofenadine in perennial allergic rhinitis (PAR) (3 arms), sponsored by Sanofi. Primary endpoints: Number of patients with adverse events at 4 weeks and Number of clinically significant abnormalities for laboratory findings at 4 weeks. Started Oct 2010; status: completed.
02
Drugs
fexofenadine
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT01244217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01244217.